Table 3 Double Refractory Characteristics.

From: Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic centers

 

All patients

 

n = 173

Age At DR/INT, (median, range)

40 (19–90)

DR/INT

 

 Double Refractory

127 (73.4)

 Intolerant

46 (26.6)

Years From Diagnosis, (median, range)

3.4 (0.5–23.1)

Prior LOT (median, range)

5 (1–13)

Prior ASCT at DR/INT

 

 Yes

86 (49.7)

 No

87 (50.3)

Treatment After DR/INT

 

 Yes

153 (88.4)

 No

20 (11.6)

BV Therapy After DR/INT

 

 Yes

41 (23.7)

 No

132 (76.3)

Anti-PD-1 Therapy After DR/INT

 

 Yes

63 (36.4)

 No

110 (63.6)

  1. Treatment characteristics for patients with DR/INT classic Hodgkin lymphoma.
  2. DR Double Refractory, INT Intolerant, LOT Lines of Therapy, ASCT Autologous Stem Cell Transplant, BV Brentuximab Vedotin.
Back to article page